



Biotech Daily

Tuesday July 29, 2025

Daily news on ASX-listed biotechnology companies

- * **ASX FLAT, BIOTECH DOWN: NOVA EYE UP 7%; DIMERIX, PROTEOMICS DOWN 6%**
- * **SOMNOMED UNAUDITED REVENUE UP 22% TO \$111.5m**
- * **AROA Q1 RECEIPTS UP 26% TO \$20.7m**
- * **MACH7 RECEIPTS UP 2% TO \$36m**
- * **NOVA EYE SALES UP 23% TO \$29m**
- * **RADIOPHARM \$5.4m RECEIPTS FROM LANTHEUS DEAL**
- * **ATOMO RECEIPTS UP 25% TO \$4.8m**
- * **CLEVER CULTURE RECEIPTS UP 331% TO \$4.7m**
- * **CHIMERIC \$4m RECEIPTS FROM CHARITY; 1.2 QUARTERS CASH**
- * **PRESCIENT \$6.8m SHARE PLAN, PLACEMENT, TRADING HALT**
- * **EMVISION BRAIN SCANNER TRIALS APPROVED; \$400k MILESTONE**
- * **EMYRIA, AVIVE HEALTH OPEN BRISBANE EMPAX CLINIC**
- * **EPSILON \$6.7m BRISBANE FACTORY SALE, LEASEBACK**
- * **SYNTARA DOSES 1st PHASE Ia/b SNT-9465 SKIN SCARRING VOLUNTEER**
- * **AVECHO DOSES 131 PHASE III TPM MARIJUANA INSOMNIA PATIENTS**
- * **GLOBAL CR HOLDINGS BELOW 5% OF BIOXYNE**

MARKET REPORT

The Australian stock market edged up 0.08 percent on Tuesday July 29, 2025, with the ASX200 up 6.9 points to 8,704.6 points. Fourteen of the Biotech Daily Top 40 companies were up, 16 fell, seven traded unchanged and three were untraded.

Nova Eye was the best (see below), up one cent or 6.9 percent to 15.5 cents, with 1.9 million shares traded. Aroa was up 6.0 percent; Atomo and Syntara were up more than five percent; Actinogen and Avita climbed four percent or more; Clinuvel, EBR and Immutep were up more than three percent; Clarity, Curvebeam and Nanosonics rose more than two percent; Neuren and SDI were up more than one percent; with Cochlear, CSL and Pro Medicus up by less than one percent.

Both Dimerix and Proteomics led the falls, down 6.4 percent to 51 cents and 36.5 cents, respectively, with 6.4 million and 238,306 shares traded, respectively. Imugene and Starpharma lost five percent or more; Compumedics and Micro-X fell more than four percent; 4D Medical, Amplia, Genetic Signatures, Medical Developments, Orthocell and Telix shed more than two percent; Cyclopharm, Emvision, Impedimed and Polynovo were down one percent or more; with Resmed down by 0.19 percent.

SOMNOMED

Somnomed says unaudited revenue for the year to June 30, 2025 was up 21.7 percent to \$111.5 million, compared to the prior corresponding period.

Last year, Somnomed said revenue from sales of its oral treatments for sleep-related breathing disorders and obstructive sleep apnoea for the year to June 30, 2024 was up 9.6 percent to \$91,651,069, with net loss after tax of \$12,241,726 (BD: Aug 28, 2024).

Today, the company said that customer receipts for the three months to June 30, 2025 were up 20.6 percent to \$29,343,000, compared to the prior corresponding period.

Somnomed said it expected earnings before interest, taxation, depreciation and amortization (Ebitda) to be "towards the top of the \$7 million to \$9 million guidance range".

The company said revenue for the three months to June 30, 2025 in Europe was up 26.2 percent to \$17,083,000, North America revenue increased 29.0 percent to \$11,413,000 and sales in the Asia Pacific region fell 4.4 percent to \$1,607,000.

Somnomed said that during the six months to June 30, 2025 it became "the only oral appliance company to have achieved the milestone of treating 1,000,000 patients".

The company said it was \$1,362,000 cash flow positive for the three months, with cash and equivalents of \$17,293,000 at June 30, 2025 compared to \$16,179,000 the prior year. Somnomed fell half a cent or 0.7 percent to 68 cents.

AROA BIOSURGERY

Aroa says customer receipts for the three months to June 30, 2025 were up 26.3 percent to \$NZ22,527,000 (\$A20,618,000), compared to the prior corresponding period.

Aroa said it was \$NZ1,716,000 cash flow positive for the three months, its third consecutive quarter of positive net cash flow.

The company said receipts from customers were from sales of its Myriad sheep stomach-derived extracellular matrix biomaterial products for wound regeneration.

Aroa said it reaffirmed expected revenue for the year to March 31, 2026 between \$NZ92 million to \$NZ100 million and normalized earnings before interest, taxation, depreciation and amortization (Ebitda) of \$NZ5 million to \$NZ8 million.

The company said it was \$NZ1,716,000 cash flow positive for the three months, its third consecutive quarter of positive net cash flow.

Aroa said it had cash and cash equivalents of NZ\$22,181,000 at June 30, 2025 compared to \$NZ23,889,000 at June 30, 2024.

Aroa was up 3.5 cents or six percent to 61.5 cents with one million shares traded.

MACH7 TECHNOLOGIES

Mach7 says receipts from customers for the year to June 30, 2025 were up 2.4 percent to \$35,693,000, compared to the previous corresponding period.

Mach7 said customer receipts from sales of its medical imaging software, subscription fees, maintenance, support and services for the three months to June 30, 2025 fell 20.1 percent to \$8,413,000, compared to the prior corresponding period.

The company said it had a positive cash flow of \$625,000 for the three months, the third consecutive three-month period of positive operating cash flow and had "achieved its objective of being operating cash flow positive for 2024-'25".

Mach7 said that it had cash and cash equivalents of \$23,069,000 at June 30, 2025 compared to \$26,175,000 at June 30, 2024.

Mach7 fell three cents or 6.9 percent to 40.5 cents with 1.2 million shares traded.

NOVA EYE MEDICAL

Nova Eye says sales for the year to June 30, 2025 were up 23.2 percent to \$US18,777,000 (\$A28,780,000) compared to the prior corresponding period.

Nova Eye said it had record revenue for the year, up 25.2 percent to \$29.2 million compared to \$23.3 million in the previous corresponding period (BD: Aug 26, 2024).

Last year the company was not required to file an Appendix 4C, and this year said it had \$8,733,000 in receipts from sales of its Itrack minimally invasive glaucoma surgical device and related products for the three months to June 30, 2025.

Nova Eye said it had a cash burn of \$847,000 for the three months, with cash and cash equivalents of \$5,054,000 at June 30, 2025 compared to \$6,151,000 at June 30, 2024.

Nova Eye was up one cent or 6.9 percent to 15.5 cents with 1.9 million shares traded.

RADIOPHARM THERANOSTICS

Radiopharm says receipts from customers for the year to June 30, 2025 of \$5,366,000, related to its partnership with Lantheus Holdings.

Last year, Radiopharm said that Lantheus Holdings had paid \$3.0 million for its pre-clinical assets transfer and development agreement (BD: Aug 5, 2024).

Later, the company said it may receive up-to \$US2 million (\$A3.2 million) under an agreement to conduct clinical research for Lantheus in Australia (BD: Jan 19, 2025).

Today, Radiopharm said it had a cash burn of \$7,027,000 for the three months, with cash and equivalents of \$29,117,000 at June 30, 2025 compared to \$18,575,000 the prior year.

Radiopharm was unchanged at 2.2 cents with 6.55 million shares traded.

ATOMO DIAGNOSTICS

Atomo says receipts from customers for the year to June 30, 2025 were up 24.9 percent to \$4,756,000, compared to the previous corresponding period.

Atomo said receipts from sales of its HIV self-tests, the Lumos Febridx tests for respiratory diseases and the Pascal blood-based Burnet Institute syphilis test for the three months to June 30, 2025 fell 3.6 percent to \$1,040,000.

The company said it had a cash burn of \$323,000 for the three months, with cash and equivalents of \$3,220,000 at June 30, 2025 compared to \$3,688,000 at June 30, 2024.

Atomo was up 0.1 cents or 5.6 percent to 1.9 cents.

CLEVER CULTURE SYSTEMS (FORMERLY LBT INNOVATIONS)

Clever Culture says receipts from customers for the year to June 30, 2025 were up 330.95 percent to \$4,650,000, compared to the prior corresponding period.

Clever Culture said customer receipts from sales of its automated plate assessment system (Apas) Independence instrument and software for environmental monitoring for the three months to June 30, 2025 were up 314.95 percent to \$888,000, compared to the previous corresponding period.

Clever Culture managing-director Brent Barnes said 2025 was “a turning point ... resulting in a major milestone towards becoming a sustainably profitable business”.

“Importantly, this is just the first year of establishing Apas Independence in the pharmaceutical manufacturing market,” Mr Barnes said.

The company said it had a cash burn of \$248,000 for the three months, with cash and equivalents of \$1,265,000 at June 30, 2025 compared to \$2,347,000 at June 30, 2024.

Clever Culture was up 0.2 cents or 6.7 percent to 3.2 cents with 3.1 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says receipts from customers for the year to June 30, 2025 were \$3,969,000, related to non-dilutionary funding from a US charity.

Earlier this year, Chimeric said it had \$4.0 million in non-dilutionary funding “from an undisclosed US-based philanthropic family office” to develop its CHM CDH17 for cancers (BD: Feb 27, 2025).

Today, the company said it had a cash burn of \$4,704,000 for the three months, with cash and cash equivalents of \$5,757,000 at June 30, 2025 compared to \$3,053,000 at June 30, 2024, leaving it with 1.22 quarters of cash.

Chimeric said it did not expect to continue to have a similar level of net operating cash flows and had raised \$6.6 million in a placement and expected to raise additional funds through the exercise of attaching options issued under the placement.

Chimeric was unchanged at 0.3 cents with 18.2 million shares traded.

PRESCIENT THERAPEUTICS

Prescient says it has raised \$6.8 million at four cents a share in a share purchase plan and has requested a trading halt pending a follow-on placement at the same price.

Earlier this month, Prescient said it hoped to raise \$7 million at four cents a share, a 16.7 percent discount to the 15-day volume weighted average price, in a share purchase plan to fund the “continued phase II clinical development of its targeted therapy, PTX-100” for blood cancer (BD: Jul 1, 2025).

Today, the company said the follow-on placement was a result of “requests from shareholders who would like to invest more than the \$30,000 available under the share purchase plan”.

Trading will resume on July 31, 2025.

Prescient last traded at 4.5 cents.

EMVISION MEDICAL DEVICES

Emvision says it has a \$400,000 milestone payment following ethics approval for an aeromedical study and a first responder study of its portable brain scanner for stroke.

Emvision said the funding was part of its project agreement with the Australian Stroke Alliance, which was funded by the Federal Government’s Medical Research Future Fund (MRFF), and related to a “telemedicine and road/air integration” milestone.

In 2021, the company said it would receive a total of \$8 million funded by the MRFF over five-years, which would support the development and clinical validation of its planned first responder device for air and road ambulances (BD: Sep 16, 2021).

Last year, Emvision said beginning ambulance validation pilot studies triggered a \$600,000 milestone payment from the Australian Stroke Alliance (BD: Mar 13, 2024).

Today, the company said the studies were designed to show its first responder brain scanner device could “fit seamlessly into emergency workflows and collect valuable data in the pre-hospital setting”.

Emvision said the aeromedical study would be conducted with the Royal Flying Doctor Service, with the first responder study run alongside the Melbourne Mobile Stroke Unit.

Emvision chief executive officer Scott Kirkland said that in the coming months the company would conduct “several studies to progress the development of our first responder device, which will be integral to expediting its commercialization via the [US Food and Drug Administration] 510(k) regulatory pathway”.

Emvision fell three cents or 1.7 percent to \$1.765.

EMYRIA

Emyria says it will open an Empax clinic at an Avive Health licenced private hospital in Brisbane to conduct psychedelic-assisted therapy for mental health disorders.

Last year, Emyria said it opened an Empax Centre with Perth's Pax Centre for the delivery and evaluation of 3,4 methylene-dioxy-meth-amphetamine (MDMA)-assisted therapy; and later, said it opened a second Empax Centre in Perth, which would treat patients for depression and post-traumatic stress disorder (BD: Apr 10, 2024; Apr 14, 2025).

Today, the company said the three-year contract with the Sydney-based Avive Health was expected to expand its national patient capacity with treatment commencing by 2026 following regulatory approvals and fit-out completion.

Emyria said the Brisbane centre was its first location in Queensland.

The company said the deal provided Avive Health exclusive rights to deliver its psychedelic-assisted therapy programs at the Brisbane site, along with a first right of refusal for additional clinics in Victoria and South Australia.

Emyria said the agreement showed its "ability to scale efficiently via select partnerships, supporting a capital-light expansion strategy to address heightened patient interest in the company's treatment programs tackling Australia's growing mental health crisis".

Emyria was unchanged at 4.1 cents with 8.2 million shares traded.

EPSILON HEALTHCARE

Epsilon says it has sold its Brisbane factory for \$6.7 million to an unnamed real estate investor and signed an initial 12-year leaseback agreement to continue use of the site.

Epsilon said it did "not consider the identity of the counterparty to be information that a reasonable person would expect to have a material effect" on its share price or value.

The company said the announcement contained "all material information relevant to assessing the impact of the transaction on the price or value of Epsilon securities and is not misleading by omission".

Epsilon did not disclose the commercial terms of the lease.

Epsilon managing-director Peter Giannopoulos said that "by reducing our debt burden and improving financial flexibility, we are better positioned to pursue our commercial and strategic expansion priorities, deliver value to shareholders, and support ... growth".

Epsilon was in a suspension and last traded at 2.4 cents.

SYNTARA (FORMERLY PHARMAXIS)

Syntara says it has dosed the first participant in its phase Ia/b trial of topical pan-lysyl oxidase inhibitor SNT-9465 for the treatment of hypertrophic scars.

Earlier this year, Syntara said it would conduct a 42-patient, phase Ia/b trial of its topical SNT-9465 for hypertrophic skin scarring by July 2025 (BD: Mar 18, 2025).

At that time, the company said it had developed SNT-9456 following a trial of its lysyl oxidase (LOX) enzyme inhibitor SNT-6302 and hoped to achieve anti-scarring efficacy with an "improved tolerability profile suitable for daily use".

Today, Syntara said the first phase Ia healthy-volunteer was dosed at Perth's Linear Joondalup Clinical Trial Centre, with phase Ia studying the safety and tolerability of SNT-9465 as well as an optimal dose for complete lysyl oxidase inhibition, to be followed by an open-label, phase Ib efficacy trial in hypertrophic scar patients.

The company said results were expected by July 2026 and would be used for a US Food and Drug Administration investigational new drug application.

Syntara was up 0.3 cents or 5.3 percent to six cents with 2.6 million shares traded.

AVECHO BIOTECHNOLOGY

Avecho says it has dosed 131 patients in its phase III trial of its oral marijuana tocopheryl phosphate mixture (TPM) for the treatment of insomnia.

Last year, Avecho said it dosed the first of 519 patients in a phase III trial of its oral TPM soft-gel capsule for insomnia (BD: May 16, 2024).

Today, the company said a total of 210 patients were required for a planned interim analysis, which based on expected recruitment rates was planned for "early 2026".

Avecho chief executive officer Dr Paul Gavin said the changes made to the inclusion and exclusion criteria late 2024 as well as additional trial sites "had a measurable impact on recruitment".

"We now have a clear line of sight to our interim analysis, a key milestone for the company," Dr Gavin said.

"Our focus remains on advancing the trial efficiently toward this important inflection point, and I look forward to keeping the market updated as we make continued progress," Dr Gavin said.

Avecho was up 0.05 cents or 11.1 percent to 0.5 cents with 4.4 million shares traded.

BIOXYNE

Global CR Holdings Ltd says it has reduced its shareholding and been diluted from 149,987,988 shares (7.89%) to below the five percent substantial threshold.

In a substantial shareholder notice, signed by director Donald Mackenzie Gibson, the Auckland, New Zealand-based Global CR said that on May 22, 2024, it reduced its holding from 149,987,988 shares (7.89%) to 136,885,430 shares (6.69%) through the sale of 13,102,558 shares for \$142,355, or 1.1 cents a share, and was diluted on April 22, 2024 in a share issue.

In a second notice Global CR said that on November 28, 2024 it reduced its holding from 136,885,430 shares (6.69%) to 111,633,815 shares (5.45%) through the sale of 25,251,615 shares on November 28, 2024 for \$208,309, or 0.8 cents a share.

In a third notice, Global CR said it ceased its substantial shareholding selling 15,500,000 shares on March 28, 2025 for \$575,186, or 3.7 cents a share.

Last year, Bioxyne said it had "firm commitments" to raise \$1.45 million in a capital raise at 1.0 cents a share (BD: Apr 18, 2024).

According to its most recent notice, Bioxyne had 2,164,828,732 shares on issue, meaning that Global CR retained about 4.44 percent of the company.

Bioxyne was unchanged at 4.9 cents with 3.2 million shares traded.